Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial

Prostate

Volumn 78, Issue 11, 2018, Pages 830-838

  Miller, Eric A ^a   Pinsky, Paul F ^a   Black, Amanda ^a   Andriole, Gerald L ^b   Pierre Victor, Dudith ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

false positive; overdiagnosis; prostate specific antigen

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL OUTCOME; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FALSE POSITIVE RESULT; FOLLOW UP; GLEASON SCORE; HEALTH DISPARITY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; SURVIVAL RATE; BLACK PERSON; CAUCASIAN; COLORECTAL TUMOR; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; INCIDENCE; MIDDLE AGED; MORTALITY; OVARY TUMOR; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 85045707808     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23540     Document Type: Article

References (31)

1. American Cancer Society. Cancer Facts and Figures 2017. Atlanta: American Cancer Society; 2017.
2. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104:125–132.
3. Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017; 123:592–599.
4. Postma R, Schroder FH, van Leenders GJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)–Section Rotterdam. A comparison of two rounds of screening. Eur Urol. 2007; 52:89–97.
5. Marcus PM, Kramer BS. Screening for Prostate Cancer with Prostate-Specific Antigen: What's the evidence? Am Soc Clin Oncol Educ Book. 2012;96–100. https://meetinglibrary.asco.org/record/66886/edbook
6. Pinsky PF, Prorok PC, Kramer BS. Prostate cancer screening—a perspective on the current state of the evidence. N Engl J Med. 2017; 376:1285–1289.
7. Moyer VA. Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157:120–134.
8. Shenoy D, Packianathan S, Chen AM, Vijayakumar S. Do African-American men need separate prostate cancer screening guidelines? BMC Urol. 2016; 16:19.
9. Tsodikov A, Gulati R, de Carvalho TM, et al. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. 2017; 123:2312–2319.
10. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011; 71:985–997.
11. Pietro GD, Chornokur G, Kumar NB, Davis C, Park JY. Racial Differences in the Diagnosis and Treatment of Prostate Cancer. Int Neurourol J. 2016; 20:S112–S119.
12. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010; 183:1792–1796.
13. US Preventive Services Task Force. Draft Recommendation Statement, Prostate Cancer: Screening. 2017. [7/26/2017]. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/prostate-cancer-screening1
14. Pinsky PF, Miller A, Kramer BS, et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2007; 165:874–881.
15. Grubb RL, 3rd, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008; 102:1524–1530.
16. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000; 21:273S–309S.
17. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102:605–613.
18. Incidence—SEERSurveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: 13 Regs Research Data, Nov 2016 Sub (1992-2014) Katrina/Rita Population Adjustment—Linked To County Attributes—Total U.S., 1969-2015 Counties, National Cancer InstituteDCCPS, Surveillance Research Program, released April 2017, based on the November 2016 submission.
19. Aggregated Total U.S.Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality—All COD, (1969-2014) Katrina/Rita Population Adjustment, National Cancer InstituteDCCPS, Surveillance Research Program, released December 2016. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
20. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280:969–974.
21. Barocas DA, Grubb R, 3rd, Black A, et al. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer. 2013; 119:2223–2229.
22. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004; 171:1504–1507.
23. Du XL, Fang S, Coker AL, et al. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer. 2006; 106:1276–1285.
24. Moses KA, Chen LY, Sjoberg DD, Bernstein M, Touijer KA. Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy. BMC Urol. 2014; 14:98.
25. Saltzman AF, Luo S, Scherrer JF, Carson KD, Grubb RL, 3rd, Hudson MA. Earlier prostate-specific antigen testing in African American men-Clinical support for the recommendation. Urol Oncol. 2015; 33:330. e9–17.
26. Smith DS, Bullock AD, Catalona WJ. Racial differences in operating characteristics of prostate cancer screening tests. J Urol. 1997; 158:1861–1865. Discussion 5-6.
27. Fowler JE, Jr., Bigler SA, Kilambi NK, Land SA. Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies. Urology. 1999; 53:1175–1178.
28. Pinsky PF, Andriole GL, Kramer BS, et al. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol. 2005; 173:746–750. Discussion 50-1.
29. Pinsky PF, Parnes HL, Andriole G. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. BJU Int. 2014; 113:254–259.
30. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002; 94:981–990.
31. Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening men at increased risk for prostate cancer diagnosis: model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev. 2017; 26:222–227.